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Summary
Aim.— Cardiogenic shock is associated with high mortality. We report our experience with the
short-term left ventricular axial pump Impella LP5.0 in nine patients with severe ischaemic
heart failure.Left ventricular assist
device;
Methods.— Six patients (group 1) presented with cardiogenic shock at the acute phase of an ST
elevation myocardial infarction. Three patients (group 2) had severe ischaemic cardiomyopathyAxial pump with temporary contra-indication to LVAD or transplantation. We measured haemodynamic and
metabolic variables up to 96 hours and recorded morbidity, mechanical pump failures, and
mortality up to one year postimplantation.
Abbreviations: CE, conformité européenne; ECMO, extracorporeal membrane oxygenation; IABP, intra-aortic balloon pump; INTERMACS,
nteragency Registry for Mechanically Assisted Circulatory Support.
∗ Corresponding author. Soins intensifs et urgences cardiologiques, hôpital cardiovasculaire et pneumologique Louis-Pradel,
P Lyon-Montchat, 69394 Lyon cedex 03, France. Fax: +33 4 72 35 73 41.
E-mail address: eric.bonnefoy-cudraz@adm.univ-lyon1.fr (E. Bonnefoy).
875-2136/$ — see front matter © 2011 Elsevier Masson SAS. All rights reserved.
oi:10.1016/j.acvd.2011.04.005
Impella support and cardiogenic shock 459
Results.— In all patients the Impella LP5.0 was safely placed through the right subclavian artery.
Cardiac power output increased from 0.64 (0.07) W to 0.94 (0.44) W and 1.02 (0.30) W at 24
and 72 hours, respectively. The Impella LP5.0 remained in place for 12 (7.2) days. In group 1,
ﬁve patients were in INTERMACS Proﬁle 3 at the time of pump insertion. Three could be weaned
and survived. One patient in INTERMACS Proﬁle 1 died of intractable heart failure within hours.
In group 2, two of three patients underwent heart transplantation. Haemorrhage requiring
transfusions was observed in four patients but only one case was directly related to the Impella
LP5.0.
Conclusion.— Left ventricular assistance with the Impella LP5.0 appears to be well tolerated.
It may be especially useful in patients with acute myocardial infarction complicated by cardio-
genic shock who achieve INTERMACS Proﬁle 3 with initial treatment.
© 2011 Elsevier Masson SAS. All rights reserved.
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Résumé
Objectif.— Le choc cardiogénique est associé à une mortalité élevée. Cette étude rapporte
notre expérience avec la pompe axiale Impella LP5.0 chez neuf patients atteints d’insufﬁsance
cardiaque sévère d’origine ischémique.
Méthodes.— Six patients (groupe 1) présentaient un choc cardiogénique à la phase aiguë d’un
infarctus du myocarde avec sus-décalage du segment ST. Trois patients (groupe 2) étaient por-
teurs d’une cardiopathie ischémique sévère et n’étaient temporairement éligibles ni à une
assistance ventriculaire gauche ni à une transplantation en urgence. Nous avons mesuré les
variables hémodynamiques et métaboliques jusqu’à 96 heures après l’implantation du disposi-
tif, ainsi que les défaillances de la pompe, la morbidité et la mortalité jusqu’à un an après
l’implantation.
Résultats.— Chez tous les patients le dispositif LP5.0 Impella a été placé sans complication par
voie sous-clavière droite. La puissance cardiaque a augmenté de 0,64 (± 0,07) W à 0,94 (± 0,44)
W et 1,02 (± 0,30) W à respectivement 24 et 72 heures. Le dispositif est resté en place pendant
12 (± 7,2) jours. Dans le groupe 1, cinq patients présentaient un Proﬁl INTERMACS 3 au moment
de l’insertion de la pompe. Trois ont pu être sevrés et ont survécu. Un patient, qui présentait
un Proﬁl INTERMACS 1, est décédé d’insufﬁsance cardiaque réfractaire en quelques heures.
Dans le groupe 2, deux des trois patients ont bénéﬁcié d’une transplantation cardiaque. Quatre
patients ont présenté une hémorragie nécessitant au moins une transfusion, mais seulement un
cas d’hémorragie a été causé directement par la pompe.
Conclusion.— L’assistance ventriculaire gauche avec la pompe Impella LP5.0 semble être bien
tolérée. Elle peut être particulièrement utile chez les patients présentant un infarctus aigu
du myocarde compliqué de choc cardiogénique, qui atteignent un Proﬁl INTERMACS 3 avec le
traitement initial.
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Background
In patients with acute myocardial infarction and cardiogenic
shock, treatment is based on revisualization, inotropes,
IABPs and respiratory support, in order to ensure haemo-
dynamic stabilization and allow partial recovery of left
ventricular systolic function. In some patients, the outcome
can be uneventful with quick recovery and fast wean-
ing from support. In other patients, mechanical assistance
is needed within hours [1]. These patients are described
as Proﬁle 1 in the INTERMACS classiﬁcation [2]. A third
group includes patients who, after initial improvement, are
‘stuck’ in a stable but precarious haemodynamic status; they
remain stable, with mid-level or high doses of intravenous
inotropic agents and/or an IABP (INTERMACS Proﬁles 2 or
3).
In patients with INTERMACS Proﬁles 1 to 3, additional
short-term left ventricular support can provide important
beneﬁts. In recent years, several short-term left ventricular
P
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evices have been developed. They are often associated
ith complications that limit their usefulness [3].
The Impella LP5.0 (Abiomed Europe GmbH, Aachen, Ger-
any) pump appears especially interesting. Relatively light
nd easy to implement, it provides a theoretical output
f 4 L/min while unloading the left ventricle. Moreover,
e have shown that the Impella LP5.0 can be inserted
hrough the subclavian artery, which allows mobilization of
he patient [4].
We report on the feasibility and the safety of the Impella
P5.0 based on our experience of its use in nine patients
ith ischaemic cardiogenic shock.
ethods
atientsrom November 2002 to November 2008, nine medi-
al patients (seven men, two women), mean (standard
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Cigure 1. Chest X-ray of a patient with an Impella LP5.0
mplanted through the left subclavian artery.
eviation [SD]) age 50 (14) years underwent implantation
f an Impella LP5.0 in our institution as mechanical support
or severe acute heart failure of ischaemic aetiology.
Six patients (group 1) presented with cardiogenic shock
t the acute phase of an ST-segment elevation myocar-
ial infarction and underwent primary or rescue angioplasty
P1—P6). All of these patients had inotropic support with
obutamine, an IABP and were under mechanical ventila-
ion. Most were given epinephrine or norepinephrine (n = 4).
Three patients (group 2) had severe ischaemic cardiomy-
pathy (P7—P9). The Impella LP5.0 was considered to allow
urther investigations or as a bridge to transplantation.
hese three patients were on inotropic support and had an
ABP.
mpella LP5.0
he Impella LP5.0 consists of a rotor driven by an incorpo-
ated electrical motor and an inﬂow cannula (Fig. 1). The
ump is placed through the aortic valve in the left ventri-
le, and drives blood from the left ventricle to the ascending
orta through the inﬂow cannula. The performance of the
ump depends on the rotary speed (up to 32.000 rpm) and
he pressure it is subjected to (aortic pressure minus left
entricular pressure). This pressure difference is continu-
usly registered through a pressure sensor located in front
f the rotor. The pump ﬂow in physiological conditions is
round 4 L/min. Rotational speed is set at nine increas-
ng levels on the driving console. In Europe, the device is
pproved for short-term use, for up to 10 days (CE marked).
n all patients, the pump was inserted through the sub-
lavian artery. This method has been described elsewhere
4]. In brief, under general anaesthesia and heparinization,
he right subclavian artery is exposed below the clavicle.
n 8-mm vascular graft is sutured end-to-side and clamped
losed to the anastomosis. A guidewire is introduced in the
mpella LP5.0 pump through a speciﬁc lumen to the dis-
al pigtail. The device is then introduced into the graft
nd an occluding plug around the 9-French driving cable
s tied to prevent blood loss through the graft during the
w
t
b
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mplantation manoeuvres. The guidewire and the pump are
ntroduced into the subclavian artery to the left ventricle
avity, crossing the aortic valve, under ﬂuoroscopic guid-
nce or transoesophageal echocardiography. The correct
osition of the device is conﬁrmed by ﬂuoroscopy or tran-
oesophageal echocardiography and the pressure signal at
he console. The guidewire is then removed and the device
s turned on. The graft around the cable is tied, closed to
he anastomosis, cut off 1 cm further along, and removed.
he surgical approach is closed and the driving cable with
he sheath is allowed to exit from the subclavian wound. To
emove the device, the same approach was used. Only the
emaining graft is controlled; the ties around are removed
nd the device is gently pulled back and out. The graft is
lamped and oversewn; then the surgical approach is closed.
atient management
ll patients had invasive arterial pressure monitoring. Five
atients had a Swan Ganz catheter inserted just before
mpella LP5.0 pump insertion. Patients were weaned from
notropic and vasopressor support as soon as possible. Filling
olume was primarily triggered by the right atrial pres-
ure and urine output. Organ perfusion was judged by
linical variables, urine output and evolution of blood lac-
ate levels. The IABP remained in place until inotropic
upport was discontinued. Recovery of cardiac function
as assessed by echocardiography. Angiotensin-converting
nzyme inhibitors were introduced and their dose was
ncreased as tolerated. Then low doses of beta-blocking
gents were introduced. Weaning from the pump occurred
ver several days by reducing the pump speed from eight to
wo in 2—3 days.
ata collection and statistics
atient data were collected retrospectively from the med-
cal records. Patients were classiﬁed according to the
NTERMACS classiﬁcation. This agency deﬁned seven clinical
roﬁles to describe patients included in its ventricular assist
evice registry [2]. These proﬁles provide convenient short-
and, which facilitates communication on the seriousness of
cute heart failure and clariﬁcation of target populations for
evices. Haemodynamic and laboratory data were collected
efore and up to 96 hours after Impella LP5.0 insertion. All
auses of morbidity and mechanical failures were recorded.
cute renal failure was deﬁned as urine output less than
0mL/h. Mortality was recorded during hospitalisation, and
t one month and one year postimplantation. Cardiac power
utput was measured as cardiac output times mean arterial
ressure divided by 451 [5]. Continuous data are presented
s mean (SD).
esults
atients
linical characteristics are presented in Table 1. Mean age
as 50.3 (14.0) years. The pump was inserted through
he subclavian artery in all patients. In group 1, all
ut one patient were stabilized and relieved from shock
ut showed no sustained improvement These INTERMACS
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Table 1 Baseline patient characteristics (at time of pump implantation).
Group 1 Group 2
Patient 1 2 3 4 5 6 7 8 9
Male sex 0 1 1 1 1 1 1 0 1
Age (years) 40 40 60 43 69 60 59 25 57
AMI history 0 0 0 0 0 0 1 1 1
INTERMACS Proﬁle (24-hour) P3 P3 P3 P3 P3 P1 P3 P2 P3
Diabetes mellitus 0 0 0 1 1 1 0 0 0
Occluded coronary artery LM LM LM LM LAD LAD-RCA LM RCA LAD
TIMI ﬂow grade 3 2 2 3 3 1 na na na
Systolic AP (mmHg) 130 86 108 92 76 83 137 74 102
Cardiac output (L/min) 4.4 3.9 2.5 3 4.2 5.8 na 3.0 na
Heart rate (beats/min) 120 112 86 91 70 134 90 97 117
IABP 1 1 1 1 1 1 1 0 1
Dobutamine 1 0 0 0 1 1 1 0 0
Milrinone 0 0 0 0 0 0 0 1 0
Norepinephrine 0 1 1 1 0 1 0 0 1
Epinephrine 1 0 0 0 1 1 0 0 0
Mechanical ventilation 1 1 1 1 1 1 0 0 0
Impella LP5.0 duration (days) 10 23 18 17 10 2 1 13 14
AMI to Impella LP5.0 delay (days) 2 3 9 5 9 0 na na na
GP IIb/IIIa antagonists 1 1 0 1 1 1 0 0 0
Clopidogrel 0 1 1 1 1 1 0 0
Creatinine (mol/L) 105 88 289 212 206 235 148 119 85
CRP (mg/L) 89 286 22.2 203 233 22 124 34 46
Arterial lactate (mmol/L) 2.3 0.9 0.9 1.4 1.2 15.0 1.3 1.5 9.0
pH 7.51 7.3 7.38 7.42 7.48 7.05 7.47 7.49 7.49
AMI: acute myocardial infarction; AP: arterial pressure; CRP: C-reactive protein; GP: glycoprotein; IABP: intra-aortic balloon pump;
INTERMACS: Interagency Registry for Mechanically Assisted Circulatory Support; LM: left main artery; LAD: left anterior descending
artery; na: not applicable; RCA: right coronary artery; TIMI: Thrombolysis In Myocardial Infarction.
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lProﬁle 3 patients had the Impella LP5.0 implanted on a
semi-urgent basis in the operating room. In one patient
(P6), implantation occurred as a rescue operation in the
catheterization laboratory after a failed primary percu-
taneous coronary intervention in an occluded left main
artery.
In group 2, contraindications to a long-term assist device
or urgent transplantation were history of stroke (P7), sus-
picion of colon cancer with sepsis (P9) and mental disorder
(P8).
Haemodynamic data
Haemodynamic data for the ﬁrst 72 hours were complete
in ﬁve patients (P1—P5; Table 2). Cardiac output increased
from 4.0 (0.5) L/min with IABP and inotropic support to 5.88
(2.67) L/min and 5.84 (1.42) L/min, 24 hours and 72 hours
after implantation, respectively. Cardiac power output
increased from 0.64 (0.07)W to 0.94 (0.44)W and 1.02
(0.30)W, 24 hours and 72 hours after implantation, respec-
tively. The cumulative diuresis during the 24 hours after the
implantation of the pumpwas 4083 (1989)mL, with an hourly
diuresis of 143 (81)mL.
e
b
w
wlinical evolution
roup 1 (n=6)
he Impella LP5.0 was implanted 4.7 (3.5) days after the
nset of infarction (Table 3). One patient (P6) who required
escue implantation of the pump in the catheterization
aboratory died of multiple-organ failure 48 hours later.
f the ﬁve patients alive 96 hours after implantation, one
ied of arrhythmic storm on the 10th day (P5). Four other
atients were able to be weaned from dobutamine and
orepinephrine. In these four patients, the IABP was with-
rawn 4.0 (2.3) days after Impella LP5.0 implantation. One
f these patients (P2) died on the 23rd day as the result
f a sudden massive left haemothorax while still on the
mpella LP5.0. The three other patients were able to be
eaned from the Impella LP5.0. Thereafter, one received
n implantable cardioverter-deﬁbrillator one month later
P1), another underwent heart transplantation ﬁve months
ater (P4), and the last (P2) died of heart failure six months
ater. During Impella LP5.0 support, angiotensin-converting
nzyme inhibitors were introduced in ﬁve patients and beta-
lockers in four. At the time of pump removal, three patients
ere on angiotensin-converting enzyme inhibitors and three
ere on beta-blockers.
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Table 2 Haemodynamic values before and after device implantation.
Patient Mean (SD)
1 2 3 4 5
Before
CO (L/min) 3.5 4.0 3.6 4.5 4.5 4.0 (0.5)
CP (W) 0.62 0.53 0.69 0.72 0.63 0.64 (0.07)
24-hour
CO (L/min) 4.4 9.2 3.0 8.2 4.6 5.88 (2.67)
CP (W) 0.77 1.22 0.45 1.55 0.71 0.94 (0.44)
72-hour
CO (L/min) 4.4 7.3 4.3 6.2 7.0 5.84 (1.42)
CP (W) 0.83 0.97 0.65 1.27 1.38 1.02 (0.30)
LVEF 1 month 3 weeks 1 month 1 month
0.4 0.2 0.4 0.2 0.3 (0.1)
CO: cardiac output; CP: cardiac power; LVEF: left ventricular ejection fraction.
Table 3 Clinical course, complications and outcome.
Group 1 Group 2
Patient 1 2 3 4 5 6 7 8 9
Complications Sepsis + + 0 + 0 0 0 + +
Haemorrhage 0 + + 0 0 0 + 0 +
Acute renal failure 0 0 + 0 + 0 0 0 0
Stroke 0 0 + 0 0 0 + 0 0
Survival Survival: in-hospital + 0 + + 0 0 + + 0
Survival: 1 month + 0 + + 0 0 + + 0
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fSurvival: 1 year + 0
roup 2 (n=3)
f the three patients who had an Impella LP5.0 implanted
ue to contraindication to long-term assistance or urgent
ransplantation, one (P9) died of septic shock 14 days after
mplantation. The Impella LP5.0 had allowed further time to
valuate a bowel mass that eventually proved to be a diver-
iculitis. The other two patients had heart transplantation:
ne at 13 days (P8) and the other at six months (P7) after
mplantation.
olerance and complications
he Impella LP5.0 pump remained in place for 12.0 (7.2)
ays with extremes of 1—23 days. Overall, the pump was
ell tolerated and ﬁve patients were able to sit on a chair
nd even walk with it. Two pumps were damaged during
mplantation with kinking of the pump catheter. This was
elated in one case to calciﬁcations and stenoses of the
liac artery during an initial left femoral attempt and in
he other to difﬁcult handling of the pump through direct
eft subclavian access. In both cases a new pump was suc-
essfully inserted through the right subclavian artery with
he graft technique. One pump had a severe motor dysfunc-
ion 24 hours after implantation, probably related to a lack
f proper lubrication by serum glucose; it required urgent
emoval. The ﬂow sensors of two pumps failed beyond
D
E
d0 + 0 0 + + 0
he ﬁrst week. These pumps continued to function prop-
rly. One patient had a left haemothorax 23 days after
mplantation. Surgical thoracotomy showed diffuse bleed-
ng not related to the aorta. All patients presented signs
f inﬂammation or sepsis during their stay, which led to
ntibiotic coverage. Three patients had germs identiﬁed
n blood culture during Impella LP5.0 assistance: pneumo-
occi (P4), staphylococcus aureus (P1) and cytomegalovirus
n sigmoid biopsies and bronchial aspiration (P9). Haemor-
hage with anaemia requiring transfusions was observed in
our patients: haemothorax (P2), haemoperitoneum (P9),
pper gastrointestinal bleeding (P3), during insertion of the
ump (P7). Haemolysis required transfusions occurred in one
atient (P9) in the setting of inﬂammation and sepsis. Two
atients experienced transient ischaemic stroke (P3, P7),
elated to air embolism in one case (P7). There was a sys-
ematic presence of thrombus on the proximal portion of
he pump after withdrawal, which probably comes from the
ubclavian Dacron graft. One patient developed acute renal
ailure requiring dialysis (P5).iscussion
ven if development of short-term left ventricular assist
evices has accelerated in the past 10 years, few devices
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are available [6]. The Impella LP5.0 is a miniaturized rotary
blood pump that has the ability to unload the left ventricle
with substantial pump capacity and to limit invasiveness.
There are two CE-marked Impella Recover® systems. The
smaller device, the Impella Recover® LP2.5 is introduced
through a femoral percutaneous approach and can deliver
an output of up to 2.5 L/min. It has mainly been used as sup-
port for patients undergoing high risk percutaneous coronary
intervention [7,8].
In our series we used the larger device, the Impella
LP5.0. The 21-French Impella LP5.0 provides a maximum
4.5 L/min output. It has been mainly used for haemodynamic
support after heart surgery [9,10]. In these patients, the
Impella LP5.0 was inserted directly through the ascending
aorta. This route is cumbersome in patients with cardio-
genic shock of medical aetiology. Insertion of the Impella
LP5.0 through a surgical cutdown of a large peripheral artery
— femoral or subclavian— is preferred. In all our patients,
the Impella LP5.0 was inserted through the right subclavian
artery. Experience with the Hemopump (Medtronic, Inc.,
Minneap0olis, MN, USA), an axial pump with similar fea-
tures, had shown that the femoral approach was associated
with device-related complications such as catheter fracture
and insertion difﬁculties [9]. We developed the subclavian
approach because of failure of insertion through a calciﬁed
femoral artery and catheter fracture [4]. In our series, this
route was well tolerated and allowed early mobilization of
patients.
An IABP is the reference short-term left ventricular assist
device [5,11,12]. The Impella LP2.5 has been compared with
an IABP in a randomized trial and provided similar haemo-
dynamic support [13]. Our series has important differences.
First, the Impella LP5.0 has twice the output of the Impella
LP2.5. Second, in most of our patients, the Impella LP5.0
was associated with an IABP that had been inserted in the
catheterizations laboratory at the time of angioplasty. The
association of an IABP with the Impella LP5.0 offers some
advantages by providing unloading of the left ventricle com-
bined with higher aortic diastolic pressure. Experimental
studies have shown that, compared with the Hemopump
alone (a device similar to the Impella LP5.0), adding an
IABP was associated with similar unloading features, an
improved subendocardial ﬂow that returned to normal in the
ischaemic region but a slight reduction of the pump output
[14].
Our study looked at the feasibility, efﬁcacy and safety
of the Impella LP5.0 and gives no insight into possible
indications. Data on indications and optimal timing of inser-
tion of short-term left assist devices remain scant among
heterogeneous populations [3,9,15]. The Impella LP5.0 is
not a substitute for ECMO, which is very effective in pro-
viding emergency mechanical pulmonary and circulatory
assistance. In fact, the Impella LP5.0 pump does not add
its output (around 4 L/min) to that of the failing heart but
largely substitutes for it [10]. The additional work and out-
put of the left ventricular assist device is actually associated
with a lower endogenous cardiac output [16]. Compared
with an IABP, overall cardiac output is only slightly higher
with the Impella LP2.5 [13]. In a postcardiotomy series eval-
uating the Impella LP5.0, patients with a residual cardiac
output of 1 L/min or more above the pump ﬂow (estimated
residual cardiac function) had a 10% mortality rate, as
g
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pposed to 88% in those with a residual cardiac function
f 1 L/min or less (P < 0.001) [10]. In our series, the patient
P6) who remained in cardiogenic shock despite inotropes,
entilation and an IABP would probably have beneﬁted more
rom an ECMO.
Within the limits of our descriptive report, INTERMACS P3
atients (pulled out of shock state, haemodynamically sta-
le but still dependent on inotropes and an IABP [2]) may
epresent a population where the Impella LP5.0 device is
specially attractive. The Impella LP5.0 appears to be rela-
ively safe. As in our series, other series with Impella pumps
ave underlined the low rates of complications, bleeding
nd embolism that contrast with other short-term left ven-
ricular assist devices [17—19]. Haemodynamic support is
ot the only way in which the Impella pump might ben-
ﬁt patients. Through reduced end-diastolic pressure, the
mpella pump improves left ventricular remodelling and
oronary perfusion in patients with myocardial infarction
nd might ease recovery of cardiac function [20].
Experimentally, support by a Hemopump has lead to a
eduction of infarct size [21]. This reduction correlated with
he degree of unloading during reperfusion. In a recent
linical series, left ventricular unloading with the Impella
P2.5 after an acute myocardial infarction resulted in a
arked left ventricular recovery, suggesting a possible ben-
ﬁcial effect of mechanical unloading on postinfarct adverse
emodelling [22]. Presumably, a larger and longer left ven-
ricular discharge with the Impella LP5.0 could be associated
ith further improvement in left ventricular remodelling
nd speed up left ventricular recovery. These hypotheses
re currently being tested in a randomized study assess-
ng the clinical and economic consequences of the Impella
P5.0 in INTERMACS Proﬁle 3 patients with acute myocardial
nfarction.
onclusion
eft ventricular assistance for up to three weeks with the
mpella LP5.0 inserted through the right subclavian artery
ppears to be safe and well tolerated. This strategy may
mprove haemodynamic status and allows further time in
atients who have a transitory contraindication to trans-
lantation or long-term assistance. Based on this series, a
andomized study is currently assessing the beneﬁt of this
evice on outcome and left ventricular function in patients
ith acutemyocardial infarction complicated by cardiogenic
hock who achieved INTERMACS Proﬁle 3 with initial treat-
ent.
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